EXOZYMES INC. 8-K

What Happened
On June 26, 2026 EXOZYMES Inc. (EXOZ) filed a Form 8‑K under Regulation FD to disclose that, in a press release dated June 24, 2026, the company announced it was awarded a $2.0 million grant from the National Institutes of Health (NIH). The grant is designated to advance the company’s work on cannabinoid analogs for drug discovery.

Key Details

• $2.0 million NIH grant awarded to EXOZYMES Inc. (announced June 24, 2026).
• Purpose: support advancement of cannabinoid analogs for drug discovery (research and development focus).
• Disclosure filed on Form 8‑K (June 26, 2026) with the press release attached as Exhibit 99.1.

Why It Matters
This NIH award provides non-dilutive government funding targeted at EXOZ’s R&D program in cannabinoid analogs, which can help finance preclinical research without issuing new equity. For investors, the grant is a tangible validation of the company’s research direction and may extend runway for pipeline work; however, the 8‑K does not disclose milestones, timelines, or financial impact beyond the grant amount. Review the company’s press release and future filings for more detail on project scope, timeline, and expected next steps.